Time New York: Sun 22 Apr 03:00 am  |  Save 15% on H&R Block Online


Express Scripts Holding Company (ESRX) Upgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research upgraded shares of Express Scripts Holding Company (ESRX) from UNDERPERFORM to NEUTRAL on April 09, 2013, with a target price of $60.00.

We are reverting back to a Neutral recommendation on Express Scripts from Underperform. The company's fourth quarter 2012 adjusted earnings of $1.05 per share, while in line with the Zacks Consensus Estimate, increased 28.1% from the year-ago period. Higher revenues aided earnings in the fourth quarter of 2012. Revenues jumped 126.5% in the fourth quarter to $27.4 billion. The massive jump was attributable to the expanded product portfolio at Express Scripts due to the acquisition of Medco Health Solutions. We believe the acquisition is a definite positive for the company and should boost results further going forward.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on Express Scripts Holding Company (ESRX), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com .

<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.